An Open-Label Phase I Study of the Safety of Perifosine in Combination With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma.
Latest Information Update: 14 Jul 2012
At a glance
- Drugs Perifosine (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors AEterna Zentaris GmbH
- 05 Jul 2012 Actual end date (1 Jul 2012) added as reported by ClinicalTrials.gov.
- 05 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Jun 2012 Results published in the British Journal of Haematology, according to an AEterna Zentaris media release.